Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | The current status of PI3K inhibitors in hematological malignancies and challenges to overcome

Geoffrey Shouse • 12 Dec 2022
ASH 2022
General Umbralisib

Geoffrey Shouse, DO, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, briefly discusses the current status of PI3K inhibitors in the treatment of hematological malignancies, and further highlights the need to develop less toxic combinations with these agents. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Kite Pharma: Speakers Bureau; Beigene Inc USA: Honoraria.

More from Geoffrey Shouse

Real-world outcomes of bispecific antibody treatment in patients with double-hit lymphoma
2:48
Real-world outcomes of bispecific antibody treatment in patients with double-hit lymphoma
Geoffrey Shouse • 10 Feb 2026
Performance status outperforms comorbidities as a predictor of survival after BsAb treatment in LBCL
3:13
Performance status outperforms comorbidities as a predictor of survival after BsAb treatment in LBCL
Geoffrey Shouse • 10 Feb 2026
Copanlisib plus nivolumab in Richter's transformation or transformed NHL: Phase I results
3:18
Copanlisib plus nivolumab in Richter's transformation or transformed NHL: Phase I results
Geoffrey Shouse • 10 Feb 2026
The development of a composite comorbidity index to predict CAR-T outcomes in patients with DLBCL
0:43
The development of a composite comorbidity index to predict CAR-T outcomes in patients with DLBCL
Geoffrey Shouse • 11 Dec 2023

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals